<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03500263</url>
  </required_header>
  <id_info>
    <org_study_id>PTI-808-02</org_study_id>
    <nct_id>NCT03500263</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis</brief_title>
  <official_title>A Phase 1 / 2, Randomized, Double-Blind, Placebo-Controlled Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proteostasis Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Proteostasis Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized, double-blind, placebo-controlled, study that will be conducted at
      multiple centers in subjects with Cystic Fibrosis (CF) who are either homozygous for the
      F508del mutation or heterozygous with at least copy of the F508del mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study PTI-808-02 will enroll up to approximately 32 subjects. Subjects in the first cohort
      will receive PTI-808 and PTI-801. Following completion of Cohort 1, initiation of enrollment
      into subsequent cohorts will be based upon review and approval by the Safety Review Committee
      (SRC).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 30, 2018</start_date>
  <completion_date type="Actual">March 13, 2019</completion_date>
  <primary_completion_date type="Actual">March 13, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability measured by the number of subjects who experience adverse events and potentially significant clinical laboratory assessments, electrocardiography, physical examinations, vital signs.</measure>
    <time_frame>Baseline through Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (t1/2) of multiple oral doses of PTI-808 + PTI-801 and PTI-428 (cohorts 3 &amp; 4 only)</measure>
    <time_frame>Day 1 through 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax) of multiple oral doses of PTI-808 + PTI-801 and PTI-428 (cohorts 3 &amp; 4 only)</measure>
    <time_frame>Day 1 through 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of multiple oral doses of PTI-808 + PTI-801 and PTI-428 (cohorts 3 &amp; 4 only)</measure>
    <time_frame>Day 1 through 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1 over time</measure>
    <time_frame>Baseline through Day 21</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in sweat chloride over time</measure>
    <time_frame>Baseline through Day 21</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in weight over time</measure>
    <time_frame>Baseline through Day 21</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in BMI over time</measure>
    <time_frame>Baseline through Day 21</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain results over time</measure>
    <time_frame>Baseline through Day 21</time_frame>
    <description>Disease-specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms. Developed specifically for use in patients with a diagnosis of cystic fibrosis.
Scaling of items:
5 distinct 4-point Likert scales (e.g., always/often/ sometime/never)
Scoring:
Scores for each HRQoL domain; after recoding, each item is summed to generate a domain score and standardized. Scores range from 0 to 100, with higher scores indicating better health.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in nasal epithelial mRNA expression over time</measure>
    <time_frame>Baseline through Day 21</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in nasal protein expression over time</measure>
    <time_frame>Baseline through Day 21</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cohorts 1 and 2: PTI-808 Active Co-admin with PTI-801 Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohorts 1 and 2: PTI-808 Placebo Co-admin with PTI-801 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 PTI-808 Active + PTI-801 Active + PTI-428 Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 PTI-808 placebo + PTI-801 Placebo + PTI-428 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 PTI-808 Active + PTI-801 Active + PTI-428 Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for 7 days immediately followed by PTI-808 co-administered with PTI-801 or placebos once-a-day for 7 days. A follow-up visit will occur on Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 PTI-808 Placebo + PTI-801 Placebo + PTI-428 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for 7 days immediately followed by PTI-808 co-administered with PTI-801 or placebos once-a-day for 7 days. A follow-up visit will occur on Day 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTI-808</intervention_name>
    <description>Active</description>
    <arm_group_label>Cohort 3 PTI-808 Active + PTI-801 Active + PTI-428 Active</arm_group_label>
    <arm_group_label>Cohort 4 PTI-808 Active + PTI-801 Active + PTI-428 Active</arm_group_label>
    <arm_group_label>Cohorts 1 and 2: PTI-808 Active Co-admin with PTI-801 Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Cohort 3 PTI-808 placebo + PTI-801 Placebo + PTI-428 Placebo</arm_group_label>
    <arm_group_label>Cohort 4 PTI-808 Placebo + PTI-801 Placebo + PTI-428 Placebo</arm_group_label>
    <arm_group_label>Cohorts 1 and 2: PTI-808 Placebo Co-admin with PTI-801 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTI-801</intervention_name>
    <description>Active</description>
    <arm_group_label>Cohort 3 PTI-808 Active + PTI-801 Active + PTI-428 Active</arm_group_label>
    <arm_group_label>Cohort 4 PTI-808 Active + PTI-801 Active + PTI-428 Active</arm_group_label>
    <arm_group_label>Cohorts 1 and 2: PTI-808 Active Co-admin with PTI-801 Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTI-428</intervention_name>
    <description>Active</description>
    <arm_group_label>Cohort 3 PTI-808 Active + PTI-801 Active + PTI-428 Active</arm_group_label>
    <arm_group_label>Cohort 4 PTI-808 Active + PTI-801 Active + PTI-428 Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Cohort 3 PTI-808 placebo + PTI-801 Placebo + PTI-428 Placebo</arm_group_label>
    <arm_group_label>Cohort 4 PTI-808 Placebo + PTI-801 Placebo + PTI-428 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cohorts 1,2 and 4: A Confirmed diagnosis of CF with the F508del/F508del CFTR genotype
             on record, along with clinical findings consistent with CF such as chronic
             sinopulmonary disease or gastrointestinal/nutritional abnormalities

          -  Cohort 3 only: Confirmed diagnosis of CF with at least one copy of the F508del CFTR
             mutation on record, along with clinical findings consistent with CF, such as chronic
             sinopulmonary disease or gastrointestinal / nutritional abnormalities

          -  Forced expiratory volume in 1 second (FEV1) 40-90% predicted, inclusive

          -  Non-smoker and non-tobacco user for a minimum of 30 days prior to screening

          -  Cohort 3 only: A sweat chloride value of ≥60 mmol/L based on quantitative pilocarpine
             iontophoresis (as documented in the subject's medical record or as confirmed at the
             screening visit)

        Exclusion Criteria:

          -  Currently taking or has taken a CFTR modulator within 30 days prior to initial dose of
             study drugs

          -  Participation in another clinical trial or treatment with an investigational agent
             within 28 days or 5 half-lives, whichever is longer, prior to Study Day 1

          -  History of cancer within the past 5 years

          -  History of organ transplantation

          -  Hospitalization, sinopulmonary infection, CF exacerbation, or other clinically
             significant infection or illness (as determined by the investigator) requiring an
             increase or addition of medication, such as antibiotics or corticosteroids, within 14
             days of Day 1

          -  Initiation of any new chronic therapy (e.g., ibuprofen, hypertonic saline,
             azithromycin, Pulmozyme®, Cayston®, TOBI®) or any change in chronic therapy (excluding
             pancreatic enzyme replacement therapy) within 28 days prior to Day 1

          -  History or current evidence of alcohol or drug abuse or dependence within 12 months of
             screening as determined by the investigator

          -  Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G514TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.proteostasis.com/clinical-trials/</url>
    <description>Information about the sponsor</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 9, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <disposition_first_submitted>March 31, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>March 31, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 6, 2020</disposition_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

